Hot Features
プレミアム
BriaCell Therapeutics Corporation (BCTX)
NASDAQ
登録してリアルタイムのチャート、分析ツール、価格を入手してください。
BriaCell Therapeutics Corp. is a clinical stage immuno-oncology company that is developing an entirely new class of targeted immunotherapies to transform cancer care. Bria-IMT(TM), BriaCell's lead candidate, was awarded Fast Track status by FDA and is being evaluated in a pivotal Phase 3 combination... BriaCell Therapeutics Corp. is a clinical stage immuno-oncology company that is developing an entirely new class of targeted immunotherapies to transform cancer care. Bria-IMT(TM), BriaCell's lead candidate, was awarded Fast Track status by FDA and is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC). MBC is breast cancer that has spread to other tissues. Bria-IMT(TM) is a targeted cell-based immunotherapy. Additionally, BriaCell is developing, Bria-OTS(TM), a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical study initially targeting breast cancer, with extension to prostate cancer, and other cancers. 詳細を表示
35 sites active and enrolling in pivotal Phase 3 study of Bria-IMT™ combination with immune check point inhibitor in metastatic breast cancer (MBC)Primary endpoint is overall survival (OS) with...
PHILADELPHIA and VANCOUVER, British Columbia, Oct. 02, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage...
PHILADELPHIA and VANCOUVER, British Columbia, Oct. 01, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage...
Dramatic anti-tumor response includes complete resolution of right temporal lobe brain metastasis in patient with “Eye-Bulging” metastatic breast cancerHeavily pre-treated patient had failed 8...
FDA has authorized the Expanded Access Policy (EAP) to help metastatic breast cancer patients in need for novel treatmentsExpanded access policy will provide potential lifesaving Bria-IMT™ to...
PHILADELPHIA and VANCOUVER, British Columbia, Sept. 12, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage...
PHILADELPHIA and VANCOUVER, British Columbia, Sept. 11, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage...
Median overall survival of 15.6 months in Phase 2 Bria-IMT™ study patients treated in combination with immune checkpoint inhibitorOS of 15.6 months compares favorably with 6.7-9.3 months reported...
BriaCell has received positive feedback from its Pre-Investigational New Drug Application (Pre-IND) meeting with FDA for Bria-PROS+™ in prostate cancerThe meeting provides a clear path towards...
PHILADELPHIA and VANCOUVER, British Columbia, Sept. 09, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage...
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.1702 | -16.8514851485 | 1.01 | 1.01 | 0.79 | 1048188 | 0.88227255 | CS |
| 4 | 0.2488 | 42.0981387479 | 0.591 | 1.42 | 0.57 | 4581773 | 0.88107058 | CS |
| 12 | 0.0786 | 10.3258013663 | 0.7612 | 1.96 | 0.4641 | 5015001 | 0.70664678 | CS |
| 26 | -1.2902 | -60.5727699531 | 2.13 | 2.44 | 0.4641 | 2513561 | 0.7258864 | CS |
| 52 | -4.8102 | -85.1362831858 | 5.65 | 5.97 | 0.4641 | 1316614 | 0.84921446 | CS |
| 156 | -7.2602 | -89.6320987654 | 8.1 | 12.47 | 0.4641 | 759290 | 3.85163489 | CS |
| 260 | -3.4002 | -80.1933962264 | 4.24 | 12.47 | 0.4641 | 1124487 | 4.78967703 | CS |
tradernewstip
5日前
glenn1919
2週前
glenn1919
3週前
Awl416
3週前
1hot toddy
3週前
1hot toddy
3週前
glenn1919
3週前
tw0122
1月前
glenn1919
1月前
Awl416
1月前
boston127
1月前
Awl416
1月前
PonkenPlonken
1月前
glenn1919
1月前
S3lfMade
1月前
subslover
1月前
Awl416
1月前
Awl416
1月前
dabonenose
1月前
Monksdream
2月前
Monksdream
3月前
Monksdream
3月前
Monksdream
3月前
Monksdream
4月前
Monksdream
4月前
Monksdream
6月前
QuicKtip
6月前
BigHeis
7月前
Monksdream
7月前
Monksdream
7月前
Monksdream
7月前
Monksdream
8月前
Monksdream
8月前
QuicKtip
11月前
Sly1969
12月前
Monksdream
12月前
benderostap4
1年前
smallcapvoice
1年前
smallcapvoice
2年前
Onree
2年前
chenzo11
2年前
Nickwvt
3年前
crudeoil24
3年前
crudeoil24
3年前
chenzo11
3年前
chenzo11
3年前
lucky__stock
3年前
lucky__stock
3年前
lucky__stock
3年前
EyalCap
3年前
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
